INS and type 2 diabetes mellitus: Thus, this review will discuss GPCRs and their signaling pathways (G protein-dependent and/or β-arrestin-dependent) that can be targeted pharmacologically to treat T2D by improving insulin sensitivity (Figures 1 and 2).